Last updated: September 24, 2026
NEFFY is ARS Pharmaceuticals' epinephrine nasal spray approved by the U.S. Food and Drug Administration in August 2024 for emergency treatment of type I allergic reactions, including anaphylaxis, in adults and pediatric patients weighing at least 30 kg. Its commercial differentiation comes from a combination of epinephrine delivery, the absorption-enhancing excipient dodecylmaltoside, and a single-use nasal device. The formulation creates opportunities in pediatric anaphylaxis, patient preference, emergency preparedness, and global licensing, while its main risks are repeat dosing, nasal-condition performance, generic formulation design-around, and adoption against established autoinjectors.[1]
What excipients are used in NEFFY nasal spray?
NEFFY uses a compact aqueous formulation with an absorption enhancer, buffer system, preservative, chelator, antioxidant, and water for injection. FDA labeling identifies the following inactive ingredients:[1]
| Excipient |
Functional role |
Commercial or regulatory relevance |
| Dodecylmaltoside |
Nasal permeation or absorption enhancer |
Core formulation differentiator; likely central to formulation IP and bioavailability |
| Benzalkonium chloride |
Preservative |
Supports multidose manufacturing controls, although NEFFY is supplied as a single-use device |
| Edetate disodium |
Chelating agent |
Binds trace metals that can accelerate epinephrine degradation |
| Sodium metabisulfite |
Antioxidant and stabilizer |
Helps limit oxidation of epinephrine; carries sulfite-sensitivity labeling |
| Sodium phosphate dibasic |
Buffer component |
Controls formulation pH and supports chemical stability |
| Sodium phosphate monobasic |
Buffer component |
Works with dibasic phosphate to maintain pH |
| Water for injection |
Vehicle |
Provides a sterile aqueous delivery medium |
The formulation strategy addresses the central technical problem with intranasal epinephrine: achieving rapid and sufficiently consistent systemic exposure without an injection. Dodecylmaltoside is the most commercially important excipient because it is intended to improve transport across the nasal mucosa. The remaining excipients support chemical stability, sterility, pH control, and shelf life.
How does dodecylmaltoside support NEFFY absorption?
Dodecylmaltoside is a nonionic surfactant used as a nasal absorption enhancer. It can increase epithelial membrane permeability and improve contact between the formulation and nasal mucosa. Its commercial value depends on whether it delivers reproducible epinephrine exposure across patients with different nasal conditions, mucus levels, congestion, or prior nasal administration.
The excipient strategy has four commercial advantages:
- It avoids the need for a needle and injection technique.
- It supports rapid systemic delivery from a small liquid volume.
- It can be integrated into a compact, portable, single-use device.
- It creates potential formulation and manufacturing barriers for generic competitors.
The same mechanism creates development constraints. Surfactant concentration, droplet distribution, viscosity, osmolality, pH, and spray plume geometry must remain within a narrow operating range. Changes can affect local tolerability, absorption rate, delivered dose, and product comparability.
What FDA regulatory status does NEFFY have?
NEFFY received FDA approval on August 9, 2024, under NDA 214697. The approved product is a 2 mg epinephrine nasal spray for adults and pediatric patients weighing 30 kg or more.[1] The approved dose is one spray into one nostril. A second dose may be administered in the same nostril after five minutes if symptoms persist or worsen, or if symptoms recur.[1]
| Regulatory item |
NEFFY status |
| Active ingredient |
Epinephrine |
| Dosage form |
Nasal spray |
| Approved strength |
2 mg per device |
| Administration |
One spray in one nostril |
| Initial approved population |
Patients weighing at least 30 kg |
| FDA approval date |
August 9, 2024 |
| Applicant |
ARS Pharmaceuticals, Inc. |
| Regulatory pathway |
New drug application |
| Biosimilar pathway |
Not applicable |
| Generic pathway |
Potential future abbreviated new drug application, subject to FDA requirements |
The product was approved after FDA requested additional data during the prior review cycle. ARS submitted additional pharmacokinetic and clinical information addressing dose delivery and repeat administration. The approval reflects the FDA's determination that NEFFY can provide an acceptable emergency alternative to injectable epinephrine for the labeled population.[1,2]
What patents protect NEFFY and its excipient strategy?
NEFFY's protection is expected to rely on a combination of formulation, nasal delivery, device, manufacturing, and method-of-use claims. The most commercially important claim categories are likely to include:
- Epinephrine formulations containing dodecylmaltoside or related absorption enhancers.
- Concentration ranges for epinephrine and excipients.
- pH, osmolality, viscosity, and stability parameters.
- Nasal spray devices that deliver a defined volume and plume.
- Methods for treating anaphylaxis with intranasal epinephrine.
- Repeat-dose protocols and emergency-use instructions.
- Manufacturing and filling processes for stable epinephrine nasal products.
The excipient strategy can create a stronger barrier than a simple active-ingredient patent because a competitor must show that its alternative formulation delivers comparable exposure, onset, safety, and usability. A generic manufacturer could attempt to replace dodecylmaltoside with another absorption enhancer, but that change would require new formulation development and comparative performance data.
Patent strength will depend on claim breadth, written-description support, patent-term adjustment, terminal disclaimers, prosecution history, and whether the FDA Orange Book lists the relevant patents. The Orange Book determines whether a listed patent can support a Paragraph IV certification and potential 30-month stay. Current patent numbers, expiration dates, and listing status should be verified against the FDA Orange Book and USPTO records before relying on them in litigation or transaction analysis.[3,4]
What is the Orange Book status of NEFFY?
NEFFY is an approved small-molecule drug and can have Orange Book-listed patents. Unlike biologic products, it does not use the Biologics Price Competition and Innovation Act pathway. Future generic applicants would generally use an ANDA and certify against relevant listed patents.
The most important Orange Book issues are:
| Issue |
Commercial effect |
| Listed formulation patent |
May support a Paragraph IV challenge and litigation |
| Listed device patent |
Can complicate substitutable generic product design |
| Method-of-use patent |
May affect labeling, but may be easier to carve out than formulation claims |
| Unlisted patent |
May support separate litigation but generally does not create the same ANDA certification framework |
| Pediatric exclusivity |
Could add six months if granted and statutory requirements are met |
| New chemical entity exclusivity |
Depends on FDA's exclusivity determination and regulatory classification |
A generic entrant would not necessarily need to use dodecylmaltoside. It could pursue a different absorption enhancer, a different nasal delivery system, or a formulation that relies on an alternative exposure profile. That approach could reduce literal infringement risk but would increase development, clinical, and regulatory risk.
When does NEFFY lose exclusivity?
The FDA approval date alone does not establish a single final loss-of-exclusivity date. The effective date depends on the applicable statutory exclusivity period, any pediatric extension, patent-term adjustment, patent-term extension, and listed patent expiration dates.
The relevant exclusivity categories are:
- New chemical entity exclusivity, if applicable.
- Five-year NCE exclusivity, subject to the statutory framework.
- Three-year exclusivity for qualifying clinical investigations supporting a new application or change.
- Pediatric exclusivity, if awarded.
- Patent protection for formulation, device, method, or manufacturing claims.
- Patent-term extension for eligible regulatory delay.
A 505(j) applicant may file a Paragraph IV certification before patent expiration and trigger litigation. Commercial launch could occur after a court ruling, settlement date, patent expiration, or an authorized-entry date. The practical generic-entry date therefore may precede the nominal expiration of the last patent.
Are there Paragraph IV challenges to NEFFY?
Publicly available approval information does not establish a mature Paragraph IV litigation record for NEFFY. Because the product launched in 2024, the relevant timing depends on when a generic manufacturer files an ANDA and when ARS receives notice of a Paragraph IV certification.
A future Paragraph IV challenge could target:
- The scope of dodecylmaltoside claims.
- The necessity of the claimed excipient concentration.
- Obviousness of combining epinephrine with a known nasal absorption enhancer.
- Enablement and written-description support for broad formulation ranges.
- Device claims covering spray volume, plume, or dose uniformity.
- Method-of-use claims covering emergency treatment and repeat dosing.
The strongest litigation position would likely come from claims that connect the excipient system to a measurable pharmaceutical result, such as rapid exposure, dose proportionality, stability, or performance under specified nasal conditions. Broad claims limited to listing known ingredients may face greater validity pressure.
What commercial opportunities does the NEFFY excipient platform create?
Pediatric and school-market expansion
NEFFY's needle-free format may improve acceptance among children, caregivers, teachers, coaches, and school personnel. The current 30 kg threshold leaves a significant opportunity for a lower-dose pediatric product, potentially including a 1 mg strength or another dose calibrated to lower body weight.
A pediatric product would require separate dose justification, device validation, stability data, usability studies, and potentially additional labeling negotiations. The existing excipient platform could reduce development time if the lower-dose product preserves the same absorption-enhancing mechanism and device architecture.
Food allergy and community emergency use
NEFFY can compete for placement in schools, restaurants, airlines, workplaces, sports facilities, and emergency kits. These channels value compact storage, ease of administration, and reduced needle anxiety. Institutional purchasing may also favor products with lower training requirements.
International licensing
The platform may be attractive to regional pharmaceutical companies with established allergy, emergency medicine, or pediatric sales channels. Licensing value would depend on:
- Local regulatory acceptance of pharmacokinetic bridging.
- Requirements for device and combination-product approval.
- Availability of dodecylmaltoside or qualified substitutes.
- Local epinephrine pricing and reimbursement.
- Patent coverage outside the United States.
- Country-specific rules for emergency medicines and pharmacy substitution.
Lifecycle management
Potential line extensions include:
- Lower-dose pediatric NEFFY.
- Two-device emergency packs.
- Formulations with longer shelf life.
- Improved cold-chain or high-temperature stability.
- Products optimized for nasal congestion or rhinitis.
- Hospital and ambulance configurations.
- Combination emergency kits with allergy action-plan tools.
How does NEFFY compare with EpiPen and Auvi-Q?
| Attribute |
NEFFY |
EpiPen |
Auvi-Q |
| Administration |
Nasal spray |
Auto-injector |
Auto-injector |
| Needle required |
No |
Yes |
Yes |
| Active ingredient |
Epinephrine |
Epinephrine |
Epinephrine |
| Key differentiation |
Nasal absorption enhancer and needle-free use |
Established market presence |
Compact device and voice guidance |
| Main technical risk |
Nasal variability and repeat-dose performance |
Injection fear and administration errors |
Device complexity and price |
| Generic competition |
Formulation and device design required |
Established generic competition |
Device and formulation competition |
| Primary commercial opportunity |
Patients and caregivers reluctant to use needles |
Broad established emergency market |
Patient-friendly injection platform |
NEFFY competes on administration route rather than a new active ingredient. Its pricing power will depend on whether patients, prescribers, schools, and payers assign measurable value to needle avoidance and ease of use.
What manufacturing and IP barriers affect NEFFY competitors?
Manufacturing barriers include epinephrine oxidation control, low-volume sterile filling, surfactant uniformity, spray-device dose consistency, container-closure compatibility, and stability across temperature excursions. Sodium metabisulfite and edetate disodium help manage chemical degradation, but the full product remains sensitive to formulation and packaging controls.
A competitor must also demonstrate:
- Content uniformity.
- Delivered-dose uniformity.
- Spray-pattern and plume performance.
- Stability through the proposed shelf life.
- Compatibility between formulation and device components.
- Comparable systemic exposure.
- Acceptable local nasal tolerability.
- Performance after repeat administration.
These requirements make a simple "epinephrine nasal spray" difficult to substitute for the approved product. The likely competitive path is a technically differentiated formulation or device, not a direct copy.
What generic launch risks exist for NEFFY?
The main risks are:
- A generic applicant develops a non-infringing absorption-enhancer system.
- Formulation patents are narrowed or invalidated.
- Device patents do not block an alternative spray platform.
- Method-of-use claims are carved out through skinny labeling.
- FDA permits an ANDA pathway based on pharmacokinetic rather than extensive clinical data.
- Institutional buyers treat nasal and injectable products as interchangeable.
- A lower-dose pediatric product expands competition before the core product reaches broad adoption.
The principal defense is a layered estate combining composition, performance, device, manufacturing, and use claims. No single excipient claim should be assumed to provide durable exclusivity.
Key Takeaways
- NEFFY's key excipient is dodecylmaltoside, which supports nasal absorption of epinephrine.
- Phosphate buffers, sodium metabisulfite, edetate disodium, benzalkonium chloride, and water for injection support stability and product quality.
- FDA approval covers a 2 mg nasal spray for patients weighing at least 30 kg.
- The strongest commercial opportunities are pediatric lifecycle management, schools, community emergency kits, and international licensing.
- The principal patent strategy should combine formulation, device, manufacturing, and method-of-use claims.
- Generic risk will center on formulation design-around, device substitution, Paragraph IV litigation, and skinny-label strategies.
- NEFFY has no biosimilar pathway because it is a small-molecule epinephrine product.
- Current Orange Book listings, patent expiration dates, and litigation status require direct verification before transaction or litigation decisions.
FAQs
Can dodecylmaltoside be replaced in a generic NEFFY product?
Yes. A generic developer could seek a different absorption enhancer, but it would need to establish equivalent quality, exposure, performance, and safety while avoiding applicable formulation claims.
Does NEFFY contain sulfites?
FDA labeling identifies sodium metabisulfite as an inactive ingredient. The product labeling includes a warning concerning sulfite sensitivity.[1]
Is NEFFY protected by a new chemical entity patent?
NEFFY contains epinephrine, an established active ingredient. Its commercial protection is more likely to depend on formulation, device, use, manufacturing, and regulatory exclusivity than on a new chemical entity patent for epinephrine itself.
Can a generic company use an epinephrine auto-injector patent strategy for NEFFY?
No. NEFFY's principal technical issues involve intranasal delivery, absorption enhancement, spray performance, and nasal-device comparability. Auto-injector patents do not directly establish freedom to operate for a nasal product.
Could NEFFY obtain a lower-dose pediatric indication?
Yes, but a lower-dose product would require FDA-supported dose selection, product-performance data, device validation, and appropriate labeling. The current approval applies to patients weighing at least 30 kg.
References
-
U.S. Food and Drug Administration. (2024). NEFFY (epinephrine nasal spray) prescribing information. FDA.
-
U.S. Food and Drug Administration. (2024). FDA approves first nasal spray to treat anaphylaxis. FDA.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
-
U.S. Patent and Trademark Office. (2024). Patent term and patent-term adjustment resources. USPTO.
